IMPROVED CLINICAL OUTCOMES WITH THE COMBINATION THERAPY OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND A SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR IN OVERWEIGHT/OBESE PEOPLE WITH TYPE 2 DIABETES: REAL-WORLD EVIDENCE FROM THE INDIAN SUBCONTINENT

Descargar Publicación
The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities